Specify a stock or a cryptocurrency in the search bar to get a summary
Inoviq Ltd
IIQINOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia. Address: 23 Normanby Road, Notting Hill, VIC, Australia, 3168
Analytics
WallStreet Target Price
5.26 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IIQ
Dividend Analytics IIQ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IIQ
Stock Valuation IIQ
Financials IIQ
Results | 2019 | Dynamics |